MARKET

QLGN

QLGN

Qualigen Therapeutics Inc
NASDAQ
0.4000
0.0000
0.00%
Closed 16:00 03/28 EDT
OPEN
0.3900
PREV CLOSE
0.4000
HIGH
0.4000
LOW
0.3582
VOLUME
79.81K
TURNOVER
0
52 WEEK HIGH
1.260
52 WEEK LOW
0.3370
MARKET CAP
2.07M
P/E (TTM)
-0.1082
1D
5D
1M
3M
1Y
5Y
Qualigen Therapeutics Ends Deal with Pan-RAS Holdings
TipRanks · 11h ago
Weekly Report: what happened at QLGN last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at QLGN last week (0311-0315)?
Weekly Report · 03/18 12:11
Weekly Report: what happened at QLGN last week (0304-0308)?
Weekly Report · 03/11 12:06
Weekly Report: what happened at QLGN last week (0226-0301)?
Weekly Report · 03/04 12:09
12 Health Care Stocks Moving In Tuesday's Intraday Session
Janux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. Viking Therapeutic shares moved upwards by 91.96% as the company's Q4 earnings report came out.
Benzinga · 02/27 17:31
Qualigen Therapeutics Secures Investment and Expands Financing Options
TipRanks · 02/27 12:12
Weekly Report: what happened at QLGN last week (0219-0223)?
Weekly Report · 02/26 12:29
More
About QLGN
Qualigen Therapeutics, Inc. is a diversified life sciences company. The Company is focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. Its cancer therapeutics pipeline includes QN-302, RAS and QN-247. QN-302 is a small molecule genomic quadruplex (G4) selective transcription inhibitor with a strong binding affinity to G4s prevalent in cancer cells. RAS is a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules for preventing mutated RAS genes’ proteins from binding to their effector proteins; preventing this binding could stop tumor growth, especially in RAS-driven tumors such as pancreatic, colorectal and lung cancers. QN-247 is a deoxyribonucleic acid (DNA) coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer, including triple negative breast cancer, acute myeloid leukemia (AML) and glioblastoma.

Webull offers Qualigen Therapeutics Inc stock information, including NASDAQ: QLGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QLGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QLGN stock methods without spending real money on the virtual paper trading platform.